Please assess the completion status of the following clinical trial:

Trial Title: Glutamatergic Modulation of Disordered Alcohol Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Active alcohol dependence. In the case of the use of other drugs, alcohol is designated as the primary drug. At least four heavy drinking day over the past 7 days (\>4 drinks a day for males, \>3 drinks for females) OR minimum weekly use of 35 drinks for males and 28 for females~* Physically healthy~* No adverse reactions to study medications~* 21-69 years of age~* Capacity to consent and comply with study procedures, including sufficient proficiency in English~* Seeking to reduce or stop alcohol use~Exclusion Criteria:~* Meets criteria for current major depression, bipolar disorder, schizophrenia, any psychotic illness, including substance induced psychosis, and current substance-induced mood disorder.~* Physiological dependence on another substance requiring medical management, such as opiods or benzodiazepines, excluding caffeine, nicotine, and cannabis~* Delirium, Dementia, Amnesia, Cognitive Disorders, or Dissociative disorders. Significant dissociative symptoms~* Current suicide risk or a history of suicide attempt within the past year~* Inability to safely initiate 24 hours of abstinence from alcohol; repeated inability to initiate abstinence during the trial without incurring significant withdrawal; history of severe withdrawal phenomena over the past 6 months (e.g., withdrawal-related seizure); or self-reported inability to maintain abstinence for 24 hours without substantial distress.~* Pregnant or interested in becoming pregnant during the study period~* Any of the following cardiac conditions: clinically significant left ventricular hypertrophy, angina, clinically significant arrhythmia, or mitral valve prolapse~* Unstable physical disorders which might make participation hazardous such as end-stage AIDS, hypertension (\>140/90), leukopenia, active hepatitis or other liver disease with elevated transaminase levels (\< 2-3 X upper limit of normal will be considered acceptable if clotting factors are normal), renal failure, epilepsy, or untreated diabetes~* Previous history of study medication misuse or abuse, and a history of an adverse reaction/experience with prior exposure to study medications~* Recent history of significant violence (past 2 years)~* First degree relative with a psychotic disorder (bipolar disorder, schizophrenia, schizoaffective disorder, or psychosis NOS)~* obesity~* On psychotropic or other medications whose effect could be disrupted by participation in the study~* BMI \> 35

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- CI-581a+MET (Type: EXPERIMENTAL): Administration of CI-581a during wk 2 at 0.71 mg/kg in the context of a 5 wk course of MET
- CI-581b+MET (Type: ACTIVE_COMPARATOR): Administration of CI-581b during wk 2 at 0.025 mg/kg in the context of a 5 wk course of MET

Based on this trial design, predict the completion outcome and termination type (if applicable).